China developed diabetes drug highlights biopharma surge
Ti Gong The Efsubaglutide alfa injection pen. Shanghai-based Innogen Pharma is set to shake up the diabetes treatment market with the approval of efsubaglutide alfa, a human-derived, long-acting GLP-1 receptor…
Read More
0
